|
Protocol Number:
01-C-0129
- Title:
Eligibility Screening and Tissue Procurement for the National Cancer Institute (NCI) Center for Cancer Research (CCR) Clinical Protocols
- Number:
01-C-0129
- Summary:
The purpose of this protocol is to provide patients with adequate informed consent to understand that screening tests with minimal health risk will be performed to evaluate their eligibility for a research study. The protocol makes it clear that patients initial visit to the intramural clinical program may include screening studies that are not medically necessary for disease management, but are done purely for research purposes.
Patients with a known or suspected diagnosis of cancer, HIV infection, skin disorder or immunodeficiency who are being considered for enrollment in a National Cancer Institute intramural clinical research protocol will participate in this consent protocol. It informs patients of screening tests and procedures involving minimal risk that are done for research purposes only, including blood tests, electrocardiogram, standard X-rays (e.g., chest X-ray), bone films, computed tomography (CT), magnetic resonance imaging (MRI), and nuclear medicine studies. It explains that other eligibility screens that are more invasive and involve greater risk, such as a biopsy, will require separate consent.
- Sponsoring Institute:
-
National Cancer Institute (NCI)
- Recruitment Detail
- Type:
Active Accrual Of New Subjects
- Gender:
Male & Female
- Referral Letter Required:
No
- Population Exclusion(s):
None
- Eligibility Criteria:
INCLUSION CRITERIA:
Patients who are being evaluated for and treated on protocols within the CCR.
All patients or their legal guardians (if the patient is less than 18 years of age) must sign a document of informed consent indicating their understanding of the research nature and the risks of the procedures that will be performed to assess eligibility for research protocols.
Patients or their parents/guardians can refuse to participate in the tissue procurement portion of this protocol and still participate in the screening eligibility on CCR research trials.
A Durable Power of Attorney will be offered to all patients greater than 18 years of age who are potentially cognitively impaired.
EXCLUSION CRITERIA:
None
- Special Instructions:
Currently Not Provided
- Keywords:
-
Screening
-
Cancer
-
AIDS
- Recruitment Keywords:
-
HIV
-
Skin Disorders
-
Cancer
-
Screening
- Conditions:
-
Cancer
-
HIV Infection
-
Skin Disease
- Investigational Drug(s):
- None
- Investigational Device(s):
- None
- Contacts:
-
Susan L. Bakke, R.N.
National Institutes of Health
Building 10
Room 12N226
10 Center Drive
Bethesda, Maryland 20892 Phone: (301) 435-5610 Fax: (301) 480-7281 Electronic Address: bakkes@mail.nih.gov
- Citations:
Not Provided
If you have:
Search The Studies | Help | Questions | Clinical Center Home | NIH Home
Warren Grant Magnuson Clinical Center (CC) National Institutes of Health (NIH)
Bethesda, Maryland 20892. Last update: 10/16/2004
|
|